Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013		Sep. 30, 2012
Cash flows from operating activities
Net cash provided by operating activities	$ 3,003		$ 19,536
Cash flows from investing activities
Capital expenditures for property, plant and equipment	(21,187)		(46,245)
Proceeds from sale of assets	16,034		2,386
Proceeds from sale of stock of Ferro Pfanstiehl Laboratories, Inc.	16,912
Dividends received from affiliates	1,119		96
Net cash provided by (used for) investing activities	12,878		(43,763)
Cash flows from financing activities
Net borrowings under loans payable	9,223	[1]	22,087	[1]
Proceeds from revolving credit facility	368,317		323,151
Principal payments on revolving credit facility	(351,404)		(319,926)
Extinguishment of convertible senior notes	(35,066)
Other financing activities	(734)		760
Net cash (used for) provided by financing activities	(9,664)		26,072
Effect of exchange rate changes on cash and cash equivalents	60		(19)
Increase in cash and cash equivalents	6,277		1,826
Cash and cash equivalents at beginning of period	29,576		22,991
Cash and cash equivalents at end of period	35,853		24,817
Cash paid during the period for:
Interest	25,484		25,343
Income taxes	$ 2,905		$ 3,130

[1] Includes cash flows related to our domestic accounts receivable program, international accounts receivable sales programs as well as loans payable to banks.